Zenas BioPharma to host virtual obexelimab IgG4-RD investor event
ZBIO•Virtual investor event scheduled for Sept. 29
Zenas BioPharma will host a virtual obexelimab IgG4-RD investor event on Sept. 29, 2026, from 8:00-9:30 a.m. ET.
- Session will cover the IgG4-RD treatment landscape, unmet need, prelaunch planning, and the commercial opportunity for obexelimab if cleared by the FDA.
- The FDA accepted the obexelimab IgG4-RD BLA in August 2026; the PDUFA target action date is set for May 27, 2027.
